Novan Announces $6.0 Million Registered Direct Offering
March 14, 2023 08:00 ET
|
Novan, Inc.
DURHAM, N.C., March 14, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it has entered into definitive agreements for the issuance and sale in a...
Novan Moves Forward with Unified Corporate Branding
March 08, 2023 09:00 ET
|
Novan, Inc.
– Novan is a fully integrated pharmaceutical company with proven capabilities across drug development through to commercialization – – EPI Health adopts Novan corporate branding, creating unified...
FDA Accepts Novan’s NDA for Berdazimer Gel, 10.3% for the Treatment of Molluscum Contagiosum with a PDUFA Goal Date of January 5, 2024
March 07, 2023 08:00 ET
|
Novan, Inc.
– FDA completes filing review of application with no filing issues identified – – New Chemical Entity (“NCE”) has potential to be the first FDA-approved prescription product for molluscum in the...
Novan to Present at the Virtual Investor 2023 Companies to Watch Event
January 18, 2023 08:05 ET
|
Novan, Inc.
DURHAM, N.C., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan, will...
Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum
January 06, 2023 08:00 ET
|
Novan, Inc.
– Potential FDA approval anticipated in first quarter 2024, assuming the filing is accepted by the FDA and under standard review timelines – – Molluscum contagiosum is a viral skin infection that...
EPI Health, a Novan Company, Enters into Exclusive License Agreement with Sato Pharmaceutical Co., Ltd. for RHOFADE® in Japan
December 21, 2022 08:00 ET
|
Novan, Inc.
DURHAM, N.C., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that EPI Health, LLC, a fully consolidated subsidiary of Novan, has entered...
EPI Health, a Novan Company, Executes a $15.0 Million Financing Agreement
December 02, 2022 08:00 ET
|
Novan, Inc.
– Agreement provides immediate access to cash flow – – EPI Health leveraging accounts receivables from commercial product sales to bolster working capital needs – DURHAM, N.C., Dec. 02, 2022 ...
Novan to Participate in the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference
December 01, 2022 09:00 ET
|
Novan, Inc.
– Paula Brown Stafford, President and Chief Executive Officer of Novan to participate in a live moderated panel discussion on Thursday, December 8th at 11:00 AM ET – DURHAM, N.C., Dec. 01, 2022 ...
Novan Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 14, 2022 07:00 ET
|
Novan, Inc.
– Rhofade prescriptions increased 37% for third quarter year-to-date from prior year – – Continued progress toward submission of berdazimer gel, 10.3% (SB206) New Drug Application (NDA), targeted...
Novan to Report Third Quarter 2022 Financial Results on November 14, 2022
November 07, 2022 09:00 ET
|
Novan, Inc.
DURHAM, N.C., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its third quarter 2022 financial results on Monday,...